Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04768881
Title Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Newly Diagnosed or Recurrent Advanced Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karyopharm Therapeutics Inc
Indications

melanoma

Therapies

Pembrolizumab + Selinexor

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.